Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
In this study, the investigators conducted a phase II trial that evaluated the efficacy and
safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and
aclarubicin) in elderly patients with AML.